Episode Details

Shadd Dales and Anthony Varrell tackle two high-impact stories shaking the cannabis sector—one in the U.S., the other in Germany—with conversations you won’t want to miss if you’re following medical cannabis, DEA reform, or European market expansion.In Segment 1, we speak with Duane Boise, CEO of MMJ BioPharma Cultivation, who claims the DEA has delayed his FDA-approved cannabis research for over 2,300 days. Boise isn’t holding back—he’s publicly demanding the removal of top DEA officials while accusing the agency of ignoring illegal THC exports by major cannabis companies. His bold stance, backed by former Florida AG Pam Bondi, raises serious questions about federal cannabis policy and scientific access.In Segment 2, we shift to Germany, where the April 2024 reclassification of medical cannabis has caused patient access to surge via telehealth platforms. But not everyone’s cheering. Legal expert Franziska Katterbach (Oppenhoff) and Bloomwell CEO Niklas Kouparanis break down why the boom could backfire if regulation doesn’t catch up. The now-banned Dr. Ansay platform is the latest flashpoint—highlighting how fast things can go off the rails in a rapidly scaling cannabis market.Two interviews. Two jurisdictions. One message: cannabis reform comes with risk if the rules don’t evolve.#CannabisIndustry #MedicalCannabis #DEAReform #CannabisResearch #GermanyCannabis #TelehealthCannabis #CannabisPolicy #CannabisLegalization #CannabisCompliance Want to see last week's recap?   • This Week: Texas Targets Hemp; AYR Wellnes...  Want to see more Cannabis Reform videos?   • What the U.S. Can Learn from Ontario’s Mar...     • JD Vance: Trump Will Lead the Bitcoin Revo...     • What’s the #1 Cannabis Stock to Own in 202...     • Why Is Federal Cannabis Legalization Takin...  Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!https://newsletter.thedalesreport.com...Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web:Facebook:

Listen Now